CAS 1310746-10-1

Formula: C26H34Cl2N7O7P

InChI: InChI=1S/C26H31Cl2N7O3.H3O4P/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28;1-5(2,3)4/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31);(H3,1,2,3,4)

InChI key: GUQNHCGYHLSITB-UHFFFAOYSA-N

SMILES: CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O

Infigratinib phosphate

CAS: 1310746-10-1

Infigratinib phosphate

Formula: C₂₆H₃₄Cl₂N₇O₇P

Purity: ≥98%

Molecular weight: 658.47

Ref: 54-BUP14247

NVP BGJ398 phosphate

CAS: 1310746-10-1

Formula: C₂₆H₃₄Cl₂N₇O₇P

Purity: 98%

Color and Shape: Solid

Molecular weight: 658.4706

Ref: IN-DA000VHN

Infigratinib phosphate

Controlled Product

CAS: 1310746-10-1

Infigratinib phosphate is a tyrosine kinase inhibitor that inhibits the growth of cells by blocking the receptor tyrosine kinases. It has been shown to be effective in treating urothelial carcinoma, cholangiocarcinoma, and other cancers. Infigratinib is a selective inhibitor of the fibroblast growth factor receptors (FGFR) 1-3 and receptor tyrosine kinases including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. Inhibiting these receptors can lead to tumor regression by blocking their signaling pathways. Infigratinib has been shown to be well tolerated in clinical trials and summarizes the effects of this drug on tumors as "rapidly progressive disease" or "progressive disease with few symptoms".

Formula: C₂₆H₃₄Cl₂N₇O₇P

Purity: Min. 95%

Molecular weight: 658.47 g/mol

Ref: 3D-KCC74610

Infigratinib phosphate

CAS: 1310746-10-1

Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and

Formula: C₂₆H₃₄Cl₂N₇O₇P

Purity: 99.24% - 99.6%

Color and Shape: Solid

Molecular weight: 658.47

Ref: TM-T16364